2023
Metformin prescription for U.S. veterans with prediabetes, 2010–2019
Gulanski B, Goulet J, Radhakrishnan K, Ko J, Li Y, Rajeevan N, Lee K, Heberer K, Lynch J, Streja E, Mutalik P, Cheung K, Concato J, Shih M, Lee J, Aslan M. Metformin prescription for U.S. veterans with prediabetes, 2010–2019. Journal Of Investigative Medicine 2023, 72: 139-150. PMID: 37668313, DOI: 10.1177/10815589231201141.Peer-Reviewed Original ResearchConceptsBody mass indexVeterans Health AdministrationIncident prediabetesHigh riskHealth AdministrationRetrospective observational cohort studyType 2 diabetes mellitusUse of metforminObservational cohort studyProportion of veteransMetformin prescribingGestational diabetesCohort studyMetformin prescriptionDiabetes mellitusDiabetes preventionMass indexCardiovascular diseaseMultivariable modelPrediabetesSubset of individualsMetforminU.S. veteransHealthcare systemVeteransEffectiveness of COVID-19 Treatment With Nirmatrelvir–Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes
Bajema K, Berry K, Streja E, Rajeevan N, Li Y, Mutalik P, Yan L, Cunningham F, Hynes D, Rowneki M, Bohnert A, Boyko E, Iwashyna T, Maciejewski M, Osborne T, Viglianti E, Aslan M, Huang G, Ioannou G. Effectiveness of COVID-19 Treatment With Nirmatrelvir–Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes. Annals Of Internal Medicine 2023, 176: m22-3565. PMID: 37276589, PMCID: PMC10243488, DOI: 10.7326/m22-3565.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntiviral AgentsCOVID-19COVID-19 Drug TreatmentCOVID-19 VaccinesFemaleHumansMaleRetrospective StudiesRitonavirSARS-CoV-2VeteransConceptsVeterans Health AdministrationCOVID-19 symptom onsetCOVID-19-related outcomesSevere COVID-19Six-month outcomesCOVID-19 vaccinationCOVID-19 treatmentCOVID-19SARS-CoV-2Percent of participantsUntreated control participantsCause mortalitySymptom onsetMedian ageOral antiviralsVHA careOutpatient treatmentHospitalizationHealth AdministrationDay 31U.S. veteransVariant transmissionMost veteransVeterans AffairsOne month
2003
Longitudinal Evaluation of Apparent Diffusion Coefficient in Children with Neurofibromatosis Type 1
Sheikh S, Kubal W, Anderson A, Mutalik P. Longitudinal Evaluation of Apparent Diffusion Coefficient in Children with Neurofibromatosis Type 1. Journal Of Computer Assisted Tomography 2003, 27: 681-686. PMID: 14501358, DOI: 10.1097/00004728-200309000-00004.Peer-Reviewed Original ResearchMeSH KeywordsBrainBrain NeoplasmsCase-Control StudiesChildDiffusion Magnetic Resonance ImagingHumansLinear ModelsNeurofibromatosis 1Retrospective StudiesConceptsInfratentorial lesionsApparent diffusion coefficientPatient agePediatric patientsSupratentorial lesionsADC of lesionsMm2 xNF1 lesionsComparison groupNeurofibromatosis type 1 patientsType 1 patientsNeurofibromatosis type 1Diffusion-weighted imagingMyelin vacuolesInfratentorial brainIntracranial lesionsNormal subjectsNormal brainSimilar lesionsLinear regression analysisLesionsLongitudinal evaluationType 1PatientsNormal children